We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+1.5%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$1.73B
Cap. Flow
-$1.75B
Cap. Flow %
-141.12%
Top 10 Hldgs %
32.38%
Holding
322
New
31
Increased
40
Reduced
64
Closed
112

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$36.4M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$12.7M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$11.6M
4
CGEM icon
Cullinan Oncology
CGEM
+$9.06M
5
ALEC icon
Alector
ALEC
+$7.87M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$24M
2
CRIS icon
Curis
CRIS
+$13.8M
3
NBP
NovaBridge Biosciences American Depositary Shares
NBP
+$13.5M
4
PRTA icon
Prothena Corp
PRTA
+$11M
5
TVRD
Tvardi Therapeutics
TVRD
+$9.32M

Sector Composition

Rank Sector Weight
1 Healthcare 43.58%
2 Technology 0.24%
3 Consumer Staples 0.11%
4 Financials 0.06%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
26
Celldex Therapeutics
CLDX
$2.79B
$12.2M 0.99%
365,544
-230,746
-39% -$6.33M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.28B
$11.9M 0.96%
640,606
+30
+0% +$553
MCRB icon
28
CALL
Seres Therapeutics
MCRB
$46.5M
$11.9M 0.96%
25,000
-14,000
-36% -$5.91M
RAPT
29
PUT
DELISTED
RAPT Therapeutics
RAPT
$11.1M 0.9%
+43,750
New +$8.17M
ARKG icon
30
PUT
ARK Genomic Revolution ETF
ARKG
$1.54B
$11.1M 0.9%
119,900
-734,100
-86% -$62.4M
MIST icon
31
Milestone Pharmaceuticals
MIST
$133M
$10.9M 0.88%
1,980,400
+143,855
+8% +$816K
SRRA
32
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$10.6M 0.86%
545,002
+99,814
+22% +$1.81M
ARNA
33
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
$10.2M 0.83%
150,000
– –
PCVX icon
34
Vaxcyte
PCVX
$7.88B
$10.1M 0.82%
448,110
-53,000
-11% -$1.09M
OCUL icon
35
CALL
Ocular Therapeutix
OCUL
$1.85B
$9.93M 0.8%
700,000
+437,900
+167% +$6.66M
RLMD icon
36
Relmada Therapeutics
RLMD
$549M
$9.61M 0.78%
300,207
+10,000
+3% +$347K
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$9.43M 0.76%
230,889
-100,100
-30% -$3.7M
AUTL
38
Autolus Therapeutics
AUTL
$386M
$9M 0.73%
1,356,048
+100,000
+8% +$621K
ANVS icon
39
Annovis Bio
ANVS
$71.9M
$8.86M 0.72%
103,527
-89,841
-46% -$4.15M
FATE icon
40
PUT
Fate Therapeutics
FATE
$270M
$8.68M 0.7%
100,000
-8,900
-8% -$717K
ITCI
41
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$8.57M 0.69%
210,000
– –
GOSS icon
42
Gossamer Bio
GOSS
$100M
$8.51M 0.69%
1,048,383
– –
CABA icon
43
Cabaletta Bio
CABA
$445M
$8.14M 0.66%
947,128
+557,744
+143% +$5.48M
MGNX icon
44
CALL
MacroGenics
MGNX
$245M
$8.06M 0.65%
300,000
+100,000
+50% +$2.93M
CGEM icon
45
Cullinan Oncology
CGEM
$1.07B
$7.61M 0.62%
295,596
+294,596
+29,460% +$9.06M
BHC icon
46
PUT
Bausch Health
BHC
$1.69B
$7.33M 0.59%
+250,000
New +$7.57M
ADCT icon
47
CALL
ADC Therapeutics
ADCT
$141M
$7.3M 0.59%
300,000
– –
ALLK
48
CALL
DELISTED
Allakos
ALLK
$6.96M 0.56%
81,500
+38,500
+90% +$3.85M
ODT
49
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$6.93M 0.56%
1,986,412
+650,000
+49% +$2.23M
LKFT
50
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$6.89M 0.56%
100,000
– –
1
2
3 4 5

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Ikarian Capital held 322 positions worth $1.24B, down 58% from $2.97B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Ikarian Capital withdrew a net $1.75B in Q2 2021, closing 112 positions and reducing 64 holdings. Its most notable exit was Curis, an estimated $13.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, up from 22% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Ikarian Capital opened a new position in ChemoCentryx, Inc. worth $6.31M.

  • Ikarian Capital's largest Q2 2021 buy was ChemoCentryx, Inc.: 471,376 shares worth $6.31M.
  • Ikarian Capital added most to Biogen in Q2 2021, an estimated $36.4M increase.
  • Ikarian Capital's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $24M.
  • Ikarian Capital fully exited Curis in Q2 2021, selling an estimated $13.8M.
  • Ikarian Capital's ten largest holdings make up 32% of its $1.24B portfolio in Q2 2021.
  • Ikarian Capital opened 31 new positions and closed 112 in Q2 2021.
  • Ikarian Capital's portfolio value fell 58% quarter-over-quarter to $1.24B.

Based on Ikarian Capital's 13F filing for Q2 2021, filed 16 Aug 2021.